These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37045931)

  • 1. Associate toxin-antitoxin with CRISPR-Cas to kill multidrug-resistant pathogens.
    Wang R; Shu X; Zhao H; Xue Q; Liu C; Wu A; Cheng F; Wang L; Zhang Y; Feng J; Wu N; Li M
    Nat Commun; 2023 Apr; 14(1):2078. PubMed ID: 37045931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systems.
    Li M; Gong L; Cheng F; Yu H; Zhao D; Wang R; Wang T; Zhang S; Zhou J; Shmakov SA; Koonin EV; Xiang H
    Science; 2021 Apr; 372(6541):. PubMed ID: 33926924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The toxin-antitoxin RNA guards of CRISPR-Cas evolved high specificity through repeat degeneration.
    Cheng F; Wu A; Liu C; Cao X; Wang R; Shu X; Wang L; Zhang Y; Xiang H; Li M
    Nucleic Acids Res; 2022 Sep; 50(16):9442-9452. PubMed ID: 36018812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Divergent degeneration of creA antitoxin genes from minimal CRISPRs and the convergent strategy of tRNA-sequestering CreT toxins.
    Cheng F; Wang R; Yu H; Liu C; Yang J; Xiang H; Li M
    Nucleic Acids Res; 2021 Oct; 49(18):10677-10688. PubMed ID: 34551428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural biology of CRISPR-Cas immunity and genome editing enzymes.
    Wang JY; Pausch P; Doudna JA
    Nat Rev Microbiol; 2022 Nov; 20(11):641-656. PubMed ID: 35562427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CRISPR/Cas system as an antimicrobial resistance strategy in aquatic ecosystems.
    Gupta SS; Hamza Kh M; Sones CL; Zhang X; Sivaraman GK
    Funct Integr Genomics; 2024 May; 24(3):110. PubMed ID: 38806846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugative Delivery of CRISPR-Cas9 for the Selective Depletion of Antibiotic-Resistant Enterococci.
    Rodrigues M; McBride SW; Hullahalli K; Palmer KL; Duerkop BA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31527030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas-Based Antimicrobials: Design, Challenges, and Bacterial Mechanisms of Resistance.
    Mayorga-Ramos A; Zúñiga-Miranda J; Carrera-Pacheco SE; Barba-Ostria C; Guamán LP
    ACS Infect Dis; 2023 Jul; 9(7):1283-1302. PubMed ID: 37347230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phage delivered CRISPR-Cas system to combat multidrug-resistant pathogens in gut microbiome.
    Nath A; Bhattacharjee R; Nandi A; Sinha A; Kar S; Manoharan N; Mitra S; Mojumdar A; Panda PK; Patro S; Dutt A; Ahuja R; Verma SK; Suar M
    Biomed Pharmacother; 2022 Jul; 151():113122. PubMed ID: 35594718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitizing pathogens to antibiotics using the CRISPR-Cas system.
    Goren M; Yosef I; Qimron U
    Drug Resist Updat; 2017 Jan; 30():1-6. PubMed ID: 28363331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas is associated with fewer antibiotic resistance genes in bacterial pathogens.
    Pursey E; Dimitriu T; Paganelli FL; Westra ER; van Houte S
    Philos Trans R Soc Lond B Biol Sci; 2022 Jan; 377(1842):20200464. PubMed ID: 34839714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
    Saha U; Gondi R; Patil A; Saroj SD
    Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas in Acinetobacter baumannii Contributes to Antibiotic Susceptibility by Targeting Endogenous
    Wang Y; Yang J; Sun X; Li M; Zhang P; Zhu Z; Jiao H; Guo T; Li G
    Microbiol Spectr; 2022 Aug; 10(4):e0082922. PubMed ID: 35938813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens.
    Shabbir MAB; Shabbir MZ; Wu Q; Mahmood S; Sajid A; Maan MK; Ahmed S; Naveed U; Hao H; Yuan Z
    Ann Clin Microbiol Antimicrob; 2019 Jul; 18(1):21. PubMed ID: 31277669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas system, antibiotic resistance and virulence in bacteria: Through a common lens.
    Roy S; Naha S; Rao A; Basu S
    Prog Mol Biol Transl Sci; 2021; 178():123-174. PubMed ID: 33685595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insertion sequences in the CRISPR-Cas system regulate horizontal antimicrobial resistance gene transfer in Shigella strains.
    Chen S; Liu H; Liang W; Hong L; Zhang B; Huang L; Guo X; Duan G
    Int J Antimicrob Agents; 2019 Feb; 53(2):109-115. PubMed ID: 30290202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of bacterial toxin-antitoxin systems in phage abortive infections].
    Hai Y; Wang X; Xie J
    Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3291-3300. PubMed ID: 36151800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas Toxin-Antitoxin Systems: Selfishness as a Constructive Evolutionary Force.
    Roy SW
    Trends Microbiol; 2021 Oct; 29(10):869-870. PubMed ID: 34376346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered CRISPR-Cas systems for the detection and control of antibiotic-resistant infections.
    Wu Y; Battalapalli D; Hakeem MJ; Selamneni V; Zhang P; Draz MS; Ruan Z
    J Nanobiotechnology; 2021 Dec; 19(1):401. PubMed ID: 34863214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.
    Yeh TK; Jean SS; Lee YL; Lu MC; Ko WC; Lin HJ; Liu PY; Hsueh PR
    Int J Antimicrob Agents; 2022 Jan; 59(1):106475. PubMed ID: 34767917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.